ArticleAmerican journal of hematology2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.
Abstract read
In one paragraph
Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies.Clinical and translational medicine · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Fieke W HoffNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-7128-1255
Joshua F ZeidnerDivision of Hematology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-9014-1514
Geeta TorlapatiThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Deedra NicoletThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Krzysztof MrózekThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Ying HuangThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Alexander LiDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Rina Li WelkieThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0001-9477-4581
Ronan T SwordsDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Elie TraerDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Eytan M SteinLeukemia Service, Department of Medicine, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Tara L LinDivision of Hematologic Malignancies, University of Kansas Medical Center, Kansas City, Kansas, USA.ORCID https://orcid.org/0000-0002-0242-6449
Maria R BaerDepartment of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
Vu H DuongDepartment of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-0278-7727
William G BlumDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Martha L ArellanoDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-1636-1962
Wendy StockSection of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
Olatoyosi OdenikeSection of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
Rebecca L OlinDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, California, USA.
Catherine C SmithDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0160-7026
Gary J SchillerDepartment of Medicine, Hematology/Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA.
Emily K CurranDivision of Hematology & Oncology, University of Cincinnati, Cincinnati, Ohio, USA.
Onyee ChanMalignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Christine McMahonDivision of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Michael HochmanDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Kieran SahasrabudheDivision of Hematology, University of Wisconsin, Carbone Cancer Center, Madison, Wisconsin, USA.
Charles FoucarDepartment of Internal Medicine, Division of Hematology and Oncology, University of New Mexico, Albuquerque, New Mexico, USA.
Jesus Gonzalez-LugoDivision of Hematologic Malignancies, University of Kansas Medical Center, Kansas City, Kansas, USA.
Brittany Knick RagonDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, USA.ORCID https://orcid.org/0000-0002-2460-0698
Shivani V HandaThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Nyla A HeeremaThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Timothy ChenThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Molly MartyczThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Mona StefanosThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Sonja G MarcusBlood Cancer United, Washington, DC, USA.
Leonard RosenbergBlood Cancer United, Washington, DC, USA.
Brian J DrukerDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Ross L LevineLeukemia Service, Department of Medicine, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Amy BurdBlood Cancer United, Washington, DC, USA.
Ashley O YocumBlood Cancer United, Washington, DC, USA.
Uma M BorateThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Alice S MimsThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
Ann-Katrin EisfeldThe James Cancer Hospital, The Ohio State University, Columbus, Ohio, USA.
John C ByrdUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Yazan F MadanatDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0001-9573-2690
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4Mblood cancer unitedHarry T. Mangurian FoundationNCI NIH HHS P30 CA008748
Abstract
Frameshift mutations in exon 12 of nucleophosmin 1 (NPM1
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteMutationNuclear ProteinsSignal TransductionSulfonamidesAgedAged, 80 and overFemalefms-Like Tyrosine Kinase 3HumansMaleMiddle AgedNucleophosminPrognosisBridged Bicyclo Compounds, HeterocyclicFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNuclear ProteinsNucleophosminSulfonamidesvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.